Altimmune Dirección
Dirección controles de criterios 2/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Vipin Garg
Chief Executive Officer (CEO)
US$5.5m
Compensación total
Porcentaje del salario del CEO | 11.3% |
Permanencia del CEO | 6yrs |
Participación del CEO | 0.4% |
Permanencia media de la dirección | 4yrs |
Promedio de permanencia en la Junta Directiva | 5.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health
Nov 13Regulatory And Clinical Catalysts Ahead For Altimmune
Oct 28Consider Buying Potential Takeover Target Altimmune
Oct 02Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects
Sep 21We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Sep 12Altimmune: Emerging Position In Competitive Space, But Risks Remain
Aug 27Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note
Jun 24Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns
May 27Buy Altimmune's Potential Market Disruption With Pemvidutide
Apr 12Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place
Mar 27Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally
Feb 27Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment
Feb 12Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
Feb 10Thoroughly Derisked, Altimmune Is Now A Great Buy
Jan 10Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?
Oct 11We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Jun 27Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth
Feb 12We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth
Oct 27Altimmune: Overreaction On NASH Data Creates Buying Opportunity
Sep 15Reassessing Altimmune
Sep 07Altimmune sets new 52-week high on rising volume
Aug 31Altimmune Q2 2022 Earnings Preview
Aug 10Altimmune: Several Catalysts In 2 Large Market Indications This Year
Jun 29Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Jun 27Altimmune's New Avatar As A Liver Disease Player
Apr 07Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Feb 01Altimmune: Changing Focus To Pemvidutide In 2022
Jan 03Altimmune: Changing The Thesis
Oct 16Análisis de compensación del CEO
Fecha | Compensación total | Salario | Ingresos de la empresa |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$104m |
Jun 30 2024 | n/a | n/a | -US$101m |
Mar 31 2024 | n/a | n/a | -US$93m |
Dec 31 2023 | US$5m | US$620k | -US$88m |
Sep 30 2023 | n/a | n/a | -US$78m |
Jun 30 2023 | n/a | n/a | -US$81m |
Mar 31 2023 | n/a | n/a | -US$85m |
Dec 31 2022 | US$3m | US$580k | -US$85m |
Sep 30 2022 | n/a | n/a | -US$87m |
Jun 30 2022 | n/a | n/a | -US$97m |
Mar 31 2022 | n/a | n/a | -US$102m |
Dec 31 2021 | US$3m | US$566k | -US$97m |
Sep 30 2021 | n/a | n/a | -US$84m |
Jun 30 2021 | n/a | n/a | -US$68m |
Mar 31 2021 | n/a | n/a | -US$60m |
Dec 31 2020 | US$1m | US$514k | -US$49m |
Sep 30 2020 | n/a | n/a | -US$43m |
Jun 30 2020 | n/a | n/a | -US$36m |
Mar 31 2020 | n/a | n/a | -US$22m |
Dec 31 2019 | US$815k | US$500k | -US$21m |
Sep 30 2019 | n/a | n/a | -US$42m |
Jun 30 2019 | n/a | n/a | -US$34m |
Mar 31 2019 | n/a | n/a | -US$40m |
Dec 31 2018 | US$2m | US$44k | -US$42m |
Compensación vs. Mercado: La compensación total de Vipin($USD5.48M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.18M).
Compensación vs. Ingresos: La compensación de Vipin ha aumentado mientras la empresa no es rentable.
CEO
Vipin Garg (66 yo)
6yrs
Permanencia
US$5,482,089
Compensación
Dr. Vipin K. Garg, Ph D., has been the President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg joined Altimmune in November 2018 with over three decades of expe...
Equipo directivo
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
President | 6yrs | US$5.48m | 0.41% $ 2.5m | |
Chief Medical Officer | 5.3yrs | US$2.24m | 0.077% $ 478.5k | |
Chief Business Officer | 1.8yrs | US$2.94m | 0.021% $ 127.2k | |
Chief Financial Officer | no data | sin datos | sin datos | |
Principal Financial & Accounting Officer and Corporate Controller | 1.8yrs | sin datos | 0.016% $ 98.7k | |
Chief Technology Officer | 7.5yrs | sin datos | sin datos | |
Chief Scientific Officer | 11.9yrs | US$1.41m | 0.061% $ 376.0k | |
Vice President of Quality & Compliance Management | 2.8yrs | sin datos | sin datos |
4.0yrs
Permanencia media
65.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ALT se considera experimentado (4 años antigüedad media).
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
President | 6yrs | US$5.48m | 0.41% $ 2.5m | |
Independent Chairman | 14.6yrs | US$119.68k | 0.037% $ 228.9k | |
Independent Director | 20.3yrs | US$103.68k | 0.0039% $ 24.1k | |
Independent Director | 7.5yrs | US$115.68k | 0.012% $ 75.8k | |
Independent Director | 7.5yrs | US$104.68k | 0.013% $ 79.7k | |
Independent Director | 1.7yrs | US$273.47k | 0% $ 0 | |
Independent Director | 6.3yrs | US$108.68k | 0.012% $ 73.8k | |
Member of Obesity Scientific Advisory Board | 2.3yrs | sin datos | sin datos | |
Independent Director | 4.5yrs | US$95.68k | 0% $ 0 | |
Member of Mash Scientific Advisory Board | 2.3yrs | sin datos | sin datos | |
Member of Mash Scientific Advisory Board | 2.3yrs | sin datos | sin datos | |
Member of Mash Scientific Advisory Board | 2.3yrs | sin datos | sin datos |
5.3yrs
Permanencia media
71.5yo
Promedio de edad
Junta con experiencia: La junta directiva de ALT se considera experimentada (5.3 años de antigüedad promedio).